Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease.
暂无分享,去创建一个
J. Ramires | L. A. César | R. Maranhão | A. Sposito | R. D. Santos | L. I. Ventura | L. César | Raul D. Santos | Andrei C. Sposito | L. A. César | J. A. Ramires
[1] C. Aguilar-Salinas,et al. Metabolic modes of action of the statins in the hyperlipoproteinemias. , 1998, Atherosclerosis.
[2] P. Vicini,et al. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[3] P. Macfarlane,et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.
[4] A. Cooper. Hepatic uptake of chylomicron remnants. , 1997, Journal of lipid research.
[5] F. Pileggi,et al. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. , 1996, Atherosclerosis.
[6] J. O’Keefe,et al. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. , 1995, The American journal of cardiology.
[7] J. Mamo,et al. CLEARANCE OF CHYLOMICRON‐LIKE LIPID EMULSIONS IS INCREASED IN NORMAL RABBITS BUT NOT IN HETEROZYGOUS WATANABE HERITABLE HYPERLIPIDAEMIC RABBITS FOLLOWING TREATMENT WITH CHOLESTYRAMINE OR PRAVASTATIN , 1994, Clinical and experimental pharmacology & physiology.
[8] A. Hamsten,et al. Postprandial lipoproteins and progression of coronary atherosclerosis. , 1994, Atherosclerosis.
[9] E. Moriguchi,et al. Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia. , 1993, Clinical biochemistry.
[10] T. D. de Bruin,et al. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. , 1993, Metabolism: clinical and experimental.
[11] B. Levkau,et al. The human asialoglycoprotein receptor is a possible binding site for low-density lipoproteins and chylomicron remnants. , 1991, The Biochemical journal.
[12] A. Hofman,et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[13] G. Coetzee,et al. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. , 1990, The Journal of clinical investigation.
[14] K. Einarsson,et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. , 1990, The New England journal of medicine.
[15] K. Cianflone,et al. Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor. , 1990, Metabolism: Clinical and Experimental.
[16] P. Edwards,et al. Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages. , 1985, The Journal of biological chemistry.
[17] R. Maranhão,et al. Metabolism of protein-free lipid emulsion models of chylomicrons in rats. , 1985, Biochimica et biophysica acta.
[18] A. Gotto,et al. Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. , 1984, The Journal of clinical investigation.
[19] D. Porte,et al. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. , 1973, The Journal of clinical investigation.
[20] H. Oliveira,et al. Simultaneous measurements of chylomicron lipolysis and remnant removal using a doubly labeled artificial lipid emulsion: studies in normolipidemic and hyperlipidemic subjects. , 1994, Journal of lipid research.